Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 11/20 | 0.81 |
| ▸ | GNAO1 | P09471 | 11/20 | 0.81 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.81 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265058 | 0.94 | GNAI3 (0.92) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL27763474 | 0.92 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL28793539 | 0.92 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL7319928 | 0.92 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL30092298 | 0.92 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL19604163 | 0.92 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL19604164 | 0.92 | GNAI3 (0.96) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL4635166 | 0.88 | GNAI3 (0.65) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL1197783 | 0.86 | GNAI3 (0.68) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL28844225 | 0.86 | GNAI3 (0.63) | GNAI3GNAO1GNAI1EPHX1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | Pelemed Co., Ltd. (KR) | 2022-06-28 | — | — | US | disclosed |
| WO-2022100710-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-05-19 | — | — | WO | disclosed |
| CN-109665987-B | Naphthaleneimide-polyamine conjugates, methods of making and uses thereof | 河南大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-109665987-A | Naphthalene lactim-polyamines conjugate and its preparation method and application | 河南大学 | 2019-04-23 | — | — | CN | disclosed |
| WO-2019013789-A1 | ANTIMICROBIAL COMPOUNDS | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2831075-B1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-8962844-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-2030963-A2 | Derivatives of 1-oxyl-4-hydroxy-or 4-amino-2,2,6,6-tetramethylpiperidine as polymerization inhibitors for (meth) acrylate monomers | Ciba Holding Inc. (CH) | 2009-03-04 | — | — | EP | disclosed |
| CN-1826323-A | 3, 4-disubstituted 1H-pyrazole compounds and their use as modulators of Cyclin Dependent Kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) | ASTEX THERAPEUTICS LTD (GB) | 2006-08-30 | — | — | CN | disclosed |
| CN-1471527-A | Quinazoline derivatives | — | 2004-01-28 | — | — | CN | disclosed |
| EP-1095006-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY-OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH) ACRYLATE MONOMERS | Ciba SC Holding AG (CH) | 2001-05-02 | — | — | EP | disclosed |
| EP-1000032-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING NITROXIDES AND OTHER COADDITIVES | Ciba SC Holding AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000003965-A1 | DERIVATIVES OF 1-OXYL-4-HYDROXY- OR 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE AS POLYMERIZATION INHIBITORS FOR (METH)ACRYLATE MONOMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-01-27 | — | — | WO | disclosed |
| US-5928558-A | STORAGE STABILITY | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1999005108-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING NITROXIDES AND OTHER COADDITIVES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-02-04 | — | — | WO | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | GNAI3 1103/4885GNAO1 1410/4885GNAI1 1087/4885 |
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | FLT3, ABL1, MCL1 | GNAI3 1147/4885GNAO1 3884/4885GNAI1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.